logo-loader
viewAntibe Therapeutics Inc

Antibe Therapeutics: Phase 2B study of flagship drug ATB-346 to treat osteoarthritis pain ‘proceeding well’

A total of 360 patients with osteoarthritis of the knee are being randomized to either placebo or one of three doses of ATB-346 administered once daily

Antibe Therapeutics - Antibe Therapeutics: Phase 2B study of flagship drug ATB-346 to treat osteoarthritis pain ‘proceeding well’
ATB-346 is a hydrogen sulfide-releasing derivative of naproxen, the most prescribed nonsteroidal anti-inflammatory drug in the US

Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) Tuesday provided an update on the Phase 2B study of its flagship drug ATB-346 to treat acute and chronic pain associated with osteoarthritis. 

“The clinical trial is proceeding well and the company is pleased with the execution and quality of patient screening, which determines admittance into the study across the 35 clinical sites,’’ Antibe said in a statement. 

The clinical study commenced in March 2019 and is designed to validate the effectiveness of ATB-346 in reducing pain and establish the dose for Phase 3 development. 

READ: Antibe Therapeutics targets US$9 billion market with second pipeline drug ATB-352 for severe pain

ATB-346 is a hydrogen sulfide-releasing derivative of naproxen, the most prescribed nonsteroidal anti-inflammatory drug (NSAID) in the US. 

A total of 360 patients with osteoarthritis of the knee are being randomized to either placebo or one of three doses of ATB-346 administered once daily -- 150 mg, 200 mg or 250 mg. 

However, Antibe said previous guidance for enrollment of the last patient had been the third quarter of 2019, which will now occur in the fourth quarter. 

The delay is largely the result of the rigorous screening discipline and a temporary slowdown in patient recruitment due to the summer holiday period, the Toronto-based company noted. 

“We have designed our clinical trial in a rigorous way and have been successful to-date in recruiting suitable patients to ensure a robust set of data,” said CEO Dan Legault. “Although this has mildly delayed our timelines, we view data quality as paramount for this trial.”

Legault went on to add that “with the recent successful financing, we’re adequately capitalized to complete the trial while funding continued development of our other programs, and anticipate being in a strong position to negotiate potential partnerships upon a successful study outcome.” 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

Quick facts: Antibe Therapeutics Inc

Price: 0.405 CAD

TSX-V:ATE
Market: TSX-V
Market Cap: $109.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Antibe Therapeutics is looking to the future after successful past year

Antibe Therapeutics  (CVE:ATE-OTCQB:ATBPF) CEO Dan Legault joined Steve Darling from the Proactive Investors Toronto studio to discuss his recent letter to the shareholders in which he outlined the company’s last year. Legault also talked about the year ahead and the prep work they...

on 07/04/2019

2 min read